Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jacqueline James

Physician Assistant, Medical Portage, MI Physician Assistant

NPI 1609069566 CMS profile 10722801

3000 Old Centre Road, Southwest Michigan Dermatology A Division Of Paragon H, Portage, MI 49024

Open in the dashboard

General payments

$7,607

371 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jacqueline James of Portage, MI is reported in the CMS Open Payments database as having received $7,607 across 371 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,526 65
2024 General $1,777 84
2023 General $1,885 90
2022 General $1,468 76
2021 General $951 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jacqueline James
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Jacqueline James were reported at $1,526. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Jacqueline James Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $951 $156 $41–$563 $132
2022 $1,468 $185 $55–$649 $149
2023 $1,885 $199 $58–$717 $160
2024 $1,777 $206 $62–$740 $164
2025 $1,526 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,546 77 payments
  2. Janssen Biotech, Inc. $906 35 payments
  3. Sun Pharmaceutical Industries Inc. $551 29 payments
  4. Amgen Inc. $477 25 payments
  5. Incyte Corporation $377 18 payments
  6. Lilly USA, LLC $360 19 payments
  7. E.R. Squibb & Sons, L.L.C. $338 18 payments
  8. Novartis Pharmaceuticals Corporation $328 21 payments
  9. UCB, Inc. $317 15 payments
  10. Genzyme Corporation $303 11 payments
  11. Other $2,103 103 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,089 364 payments
  2. Education $518 7 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $846 31 payments
  2. SKYRIZI Immunology $718 40 payments
  3. Otezla $477 25 payments
  4. DUPIXENT $449 15 payments
  5. RINVOQ $436 18 payments
  6. OPZELURA $377 18 payments
  7. TALTZ $360 19 payments
  8. SOTYKTU $317 17 payments
  9. ILUMYA $316 14 payments
  10. SKYRIZI Immunology $300 14 payments
  11. Other $3,836 214 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

786

Median for Physician Assistant: 241

Drug cost

$306,152

Median for Physician Assistant: $4,110

Branded share of claims

11.5%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Otezla Apremilast Brand 32 $152,218
Adbry Tralokinumab-Ldrm Brand 20 $78,576
Dupixent Pen Dupilumab Brand 12 $45,306
Fluorouracil Generic 75 $4,371
Doxycycline Hyclate Generic 42 $3,616
Tacrolimus Generic 21 $3,314
Desonide Generic 57 $3,304
Clobetasol Propionate Generic 86 $2,735
Triamcinolone Acetonide Generic 90 $2,372
Azelaic Acid Generic 16 $2,061

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 21 billing codes

Paid by Medicare

$59,104

Medicare's payments for the services billed

Medicare patients

399

Average age 74

Services billed

2,261

247 women, 152 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Arthritis 41%
Chronic kidney disease 20%
Ischemic heart disease 18%
Depression 18%
Diabetes 16%
Atrial fibrillation 16%
Cancer 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VTAMA
  • Dermavant Sciences, Inc. $212
$212 — —
SOTYKTU
  • E.R. Squibb & Sons, L.L.C. $181
$181 — —
TREMFYA
  • Janssen Biotech, Inc. $159
$159 — —
SKYRIZI
  • AbbVie, Inc. $158
$158 — —
ILUMYA
  • Sun Pharmaceutical Industries Inc. $128
$128 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

371 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record